红花酒改善终末期肾病患者动静脉内瘘临床效果研究进展  

Study advances in clinical effect of Safflower Wine in improving arteriovenous internal fistula in patients with end-stage renal disease

作　　者：熊燕影 钟锦[1] 黎颖(综述)[1] 熊维建[1] 李凡(审校)[1] XIONG Yanying;ZHONG Jin;LI Ying;XIONG Weijian;LI Fan(Department of Nephrology,Chongqing Municipall Hospital of Traditional Chinese Medicine,Chongqing 400021,China)

机构地区：[1]重庆市中医院肾病科,400021

出　　处：《重庆医学》2021年第9期1601-1604,共4页Chongqing medicine

基　　金：国家自然科学基金青年科学基金项目(81904012);重庆市自然科学基金重庆市基础研究与前沿探索项目(cstc2018jcyjAX0783);重庆市自然科学基金科研机构绩效激励引导专项(cstc2018jxjl130048);国家中医药管理局,国医大师郑新工作室(0192)。

摘　　要：红花酒对动静脉内瘘有一定保护作用,在临床中用于促进终末期肾病(ESRD)患者动静脉内瘘(AVF)的成熟,提升ESRD患者生存质量。按照国医大师郑新“肾病多瘀论”,活血化瘀不仅是治疗肾脏疾病的重要方法之一,也是治疗AVF并发症的重要手段。本文就红花酒在改善ESRD患者AVF的临床效果进行综述。Safflower Wine has a certain protective effect on arteriovenous internal fistula,and is used in clinical practice to promote the maturation of arteriovenous internal fistula(AVF)in the patients with end-stage renal disease(ESRD)and improve the quality of life in the patients with ESRD.According to the theory of"kidney disease with multiple blood stasis"by master of traditional Chinese medical science ZHENG Xin,activating blood circulation and removing blood stasis is not only one of the important methods to treat kidney disease,but also an important means to treat the complications of AVF.This article reviews the clinical effect of Safflowera Wine in improving AVF in patients with ESRD.

关 键 词：红花酒 动静脉内瘘 终末期肾病 临床效果 研究进展 

分 类 号：R259[医药卫生—中西医结合]